SLC5A2 and metabolic syndrome: Li et al. [109] reported that SGLT-2 inhibitors are not associated with an increased risk of dyslipidemia, and they significantly decrease triglycerides (-0.12 mmol/l). A systematic review by Sánchez-García et al. [110] and a meta-analysis by Bechmann et al. [111] reported that SGLT-2 inhibitors increased low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C).